Credit: Carl/Adobe Stock

The mifepristone case, FDA v. Alliance for Hippocratic Medicine, attracted a lot of national attention not only because of its implications for reproductive rights, but also because of the question related to the FDA's regulatory power. On June 13, 2024, the decision of the Supreme Court of the United States resulted in access to mifepristone, an abortion medication, remaining unchanged, but the decision was based on a procedural issue rather than an effort to protect reproductive rights.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Benefits Sales Strategies
Broker Regulation
Core and Group Health
Health Care Reform
C-Suite
Employer-Paid